TY - JOUR
T1 - Tissue Beads
T2 - Tissue-Specific Extracellular Matrix Microbeads to Potentiate Reprogrammed Cell-Based Therapy
AU - Lee, Jung Seung
AU - Roh, Yoon Ho
AU - Choi, Yi Sun
AU - Jin, Yoonhee
AU - Jeon, Eun Je
AU - Bong, Ki Wan
AU - Cho, Seung Woo
N1 - Funding Information:
We thank the patients with AD and PD and their families, whose help and participation made this work possible, as well as the clinical and research personnel of the Center for Human Genetics at Duke University Medical Center, the Program in Human Genetics at Vanderbilt University Medical Center, and the Joseph and the Kathleen Bryan ADRC. This work was supported by grants NS31153, AG05128, P50-AG-05128, AG13308, AG11268, AG10123, MH52453, P01 NS26630, and P50 NS39764 from the National Institutes of Health; grant M01 RR00865 from the U.S. Public Health Service; grant 95-23330 from the California Department of Health Services; grants IIRG94101 and IRG2-96044 from the Fran and Ray Stark Foundation Fund for Alzheimer's Disease Research; a T. L. L. Temple Award (TLL-97-012); and Zenith Awards from the Alzheimer's Disease and Related Disorders Association and GlaxoSmithKline, Inc.
Publisher Copyright:
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
PY - 2019/8/1
Y1 - 2019/8/1
N2 - Microbeads have been utilized as efficient cell culture carriers and injectable scaffolds for cell transplantation. However, various polymers currently used to generate microbeads have limited applicability due to loss of biological functions and tissue-specific effects. Here, a tissue bead platform is reported that can provide a tissue-specific microenvironment to facilitate cell culture and potentiate cell therapy. Using a flow-focusing microfluidic device, uniform-sized tissue microbeads are fabricated with extracellular matrix (ECM) from various decellularized tissues. The tissue microbeads are tested for tissue-specific encapsulation of induced hepatic (iHep), induced cardiac (iCar), and induced myogenic (iMyo) cells, which are directly reprogrammed from mouse primary fibroblasts. Tissue-specific microbeads significantly enhanced the viability, lineage-specific maturation, and functionality of each type of reprogrammed cell, as compared to functionality when using conventional microbeads from a single ECM component (collagen). Finally, tissue microbeads are confirmed to mediate the successful in vivo engraftment of reprogrammed cells (iHep and iMyo) after transplantation, potentiating cell therapy and promoting functional tissue regeneration in tissue defective animal models. The study suggests that the use of a decellularized tissue matrix combined with a microfluidic technique can be employed to produce tissue-specific ECM microbeads with increased versatility and efficacy for reprogrammed cell-based therapy.
AB - Microbeads have been utilized as efficient cell culture carriers and injectable scaffolds for cell transplantation. However, various polymers currently used to generate microbeads have limited applicability due to loss of biological functions and tissue-specific effects. Here, a tissue bead platform is reported that can provide a tissue-specific microenvironment to facilitate cell culture and potentiate cell therapy. Using a flow-focusing microfluidic device, uniform-sized tissue microbeads are fabricated with extracellular matrix (ECM) from various decellularized tissues. The tissue microbeads are tested for tissue-specific encapsulation of induced hepatic (iHep), induced cardiac (iCar), and induced myogenic (iMyo) cells, which are directly reprogrammed from mouse primary fibroblasts. Tissue-specific microbeads significantly enhanced the viability, lineage-specific maturation, and functionality of each type of reprogrammed cell, as compared to functionality when using conventional microbeads from a single ECM component (collagen). Finally, tissue microbeads are confirmed to mediate the successful in vivo engraftment of reprogrammed cells (iHep and iMyo) after transplantation, potentiating cell therapy and promoting functional tissue regeneration in tissue defective animal models. The study suggests that the use of a decellularized tissue matrix combined with a microfluidic technique can be employed to produce tissue-specific ECM microbeads with increased versatility and efficacy for reprogrammed cell-based therapy.
KW - cell therapy
KW - decellularized tissue matrix
KW - direct reprogramming
KW - tissue-specific microbeads
UR - http://www.scopus.com/inward/record.url?scp=85065670789&partnerID=8YFLogxK
U2 - 10.1002/adfm.201807803
DO - 10.1002/adfm.201807803
M3 - Article
AN - SCOPUS:85065670789
SN - 1616-301X
VL - 29
JO - Advanced Functional Materials
JF - Advanced Functional Materials
IS - 31
M1 - 1807803
ER -